For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
PXS-5505 Multinational Trial in Myelofibrosis Cleared by Safety Committee to Advance to Second Stage of Dose Escalation Study.
Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced it has completed dosing the first of three stages in its phase 1c clinical trial (MF-101) studying a potential new treatment for the bone marrow cancer myelofibrosis. The study’s safety monitoring committee that advises on the study progress, has given the green light to progress to the second dose level after reviewing factors including the safety and pharmacokinetic properties of PXS-5505 in myelofibrosis patients.Read full media release - pdf
Pharmaxis Ltd (ASX: PXS) invites investors and analysts to participate in a virtual investor briefing by the Company’s chief executive officer Mr Gary Phillips at 11.00am AET on Friday 4 June 2021.
The event will consist of a brief presentation of the Company’s recent progress and future plans followed by a Q&A session from attendees.
The event is free to attend, and investors should register in advance using the following registration link:
Upon registration, instructions for joining the session will be sent via email.
To ensure we can get through as many questions as possible in the allotted time, Pharmaxis welcomes investors to pre-submit questions by emailing them to: email@example.comRead full media release - pdf
Unique mechanism of drug action inhibits enzymes critical to tumour growth and survival
An Australian drug discovery will be the focus of a new study to tackle an aggressive and deadly form of brain cancer with a funding grant from the Charlie Teo Foundation. The drug, developed by Sydney-based research company Pharmaxis (ASX: PXS), will enter pre-clinical efficacy testing for glioblastoma (GBM), the most common form of brain cancer with an average survival of only 15 months from diagnosis.Read full media release - pdf